Adapting Dialectical Behavior Therapy for the Treatment of Criminal Offenders With Antisocial Personality Disorder (DBT-ASPD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: BARRY ROSENFELD, PhD
- Phone Number: 718-817-3794
- Email: ROSENFELD@FORDHAM.EDU
Study Contact Backup
- Name: Michele Galietta, PhD
- Email: mgalietta@gmail.com
Study Locations
-
-
New York
-
Bronx, New York, United States, 104580000
- Fordham University Community Mental Health Clinic
-
Contact:
- BARRY ROSENFELD, PhD
- Phone Number: 718-817-3794
- Email: ROSENFELD@FORDHAM.EDU
-
Contact:
- Christopher Conway, PhD
- Phone Number: 718-817-0106
- Email: cconway26@fordham.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Over 18, English speaking, Participating in RISE Court program
Exclusion Criteria:
- Evidence of psychotic symptoms that would preclude meaningful participation in treatment.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
DBT intervention
Adaptation of Dialectical Behavior Therapy designed for repeat criminal offenders at high risk of reoffense.
|
Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completion of the treatment program
Time Frame: 4 months after initiation of treatment
|
Individuals will be classified as "completers" if they have finished the entire 16 week treatment program
|
4 months after initiation of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impulsivitity,
Time Frame: Post-treatment (approximately 4 months after initiation of treatment)
|
Impulsivity will be measured with a self-report measure, the UPPS-P Impulsivity Scale, which will be administered prior to, and following completion of treatment
|
Post-treatment (approximately 4 months after initiation of treatment)
|
|
Distress tolerance
Time Frame: Post-treatment (approximately 4 months after initiation of treatment)
|
Distress tolerance will be measured with a self-report measure, the Distress Tolerance Scale, which will be administered prior to, and following completion of treatment
|
Post-treatment (approximately 4 months after initiation of treatment)
|
|
Emotion regulation
Time Frame: Post-treatment (approximately 4 months after initiation of treatment)
|
Distress tolerance will be measured with a self-report measure, the Difficulties in Emotion Regulation Scale, which will be administered prior to, and following completion of treatment
|
Post-treatment (approximately 4 months after initiation of treatment)
|
|
Mindfulness
Time Frame: Post-treatment (approximately 4 months after initiation of treatment)
|
Mindfulness will be measured with a self-report measure, the Mindful Attention Awareness Scale, which will be administered prior to, and following completion of treatment
|
Post-treatment (approximately 4 months after initiation of treatment)
|
|
Renewed criminal charges following completion of treatment
Time Frame: 1 year
|
Participants will be monitored for at least one year following treatment in order to determine whether they have been charged with any additional criminal offenses
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Barry Rosenfeld, PhD, Fordham University
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 957186
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.